Rare essentials: drugs for rare diseases as essential medicines
Bulletin of the World Health Organization, 2006 Since 1977, the WHO Model List of Essential Medicines (EML), published by WHO, has provided advice for Member States that struggle to decide which pharmaceutical technologies should be provided to patients within their public health systems.
Pieter Stolk +2 more
doaj +6 more sources
Survey and analysis of the availability and affordability of essential drugs in Hefei based on WHO / HAI standard survey methods [PDF]
BMC Public Health, 2020 Background The 2018 edition of the National Essential drugs List came into effect in September 2018. Relevant policies require that all primary medical and health institutions should supply national essential drugs, while secondary and tertiary medical ...
Zuojun Dong, Qiucheng Tao, Guojun Sun
doaj +2 more sources
Evaluating the availability of essential drugs for hypertension, diabetes and asthma in rural Rwanda, 2018. [PDF]
Public Health Action, 2021 Mbonyinshuti F +7 more
europepmc +2 more sources
Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysis. [PDF]
BMJ Open, 2019 Hua Z +10 more
europepmc +3 more sources
Study on the Relationship Between the Number of Adverse Drug Reactions of Essential Drugs and Visits: Based on Vector Autoregressive Model. [PDF]
Risk Manag Healthc Policy, 2023 Tang W, Chen H, Zhang Z, Wu G, Lin Y.
europepmc +2 more sources
A third-line antiretroviral therapy register to track patient clinical and virological outcomes
South African Medical Journal, 2022 -
K Naidoo +3 more
doaj +1 more source
Indian Journal of Medical Specialities, 2021 Background: Globally, pharmacovigilance, rationality of drug prescription studies, and adverse drug reaction (ADR) in children affected with ailments are an understudied topic.
Farangipet Fathima +6 more
doaj +1 more source
Health Systems & Reform, 2021 Evidence shows that those with non-communicable diseases (NCDs) are at higher risk for serious illness and mortality from COVID-19. In Kenya, about 50% of the COVID-19 patients who have died had an NCD.
Zana Wangari Kiragu +9 more
doaj +1 more source
Journal of Nature and Science of Medicine, 2022 Background: Implications from accumulated bodies of commentaries and media/social-media reports highlight the drug shortage during the COVID-19 pandemic. In this special report, the relation between drug shortage and response measures is discussed in the
Mohammed Salahuddin +4 more
doaj +1 more source
Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB. [PDF]
, 2016 Repurposing has gained momentum globally and become an alternative avenue for drug discovery because of its better success rate, and reduced cost, time and issues related to safety than the conventional drug discovery process.
Brindha, Sridharan +4 more
core +1 more source